[S02DA03, antipyrine, The risk or severity of hypertension can be increased when Methylphenidate is combined with Antipyrine.]
[M01AB02, sulindac, The risk or severity of hypertension can be increased when Methylphenidate is combined with Sulindac.]
[N05AL01, sulpiride, The risk or severity of adverse effects can be increased when Sulpiride is combined with Methylphenidate.]
[N03AX03, sulthiame, The therapeutic efficacy of Sulthiame can be decreased when used in combination with Methylphenidate.]
[M01AX04, apazone, The risk or severity of hypertension can be increased when Methylphenidate is combined with Azapropazone.]
[R03CC03, terbutaline, The risk or severity of hypertension can be increased when Methylphenidate is combined with Terbutaline.]
[N05AE05, lurasidone, The risk or severity of adverse effects can be increased when Lurasidone is combined with Methylphenidate.]
[N04BC07, apomorphine, The risk or severity of adverse effects can be increased when Methylphenidate is combined with Apomorphine.]
[R06AD03, thiethylperazine, The risk or severity of adverse effects can be increased when Thiethylperazine is combined with Methylphenidate.]
[N05CA19, thiopental, The therapeutic efficacy of Thiopental can be decreased when used in combination with Methylphenidate.]
[N05AB08, thioproperazine, The risk or severity of adverse effects can be increased when Thioproperazine is combined with Methylphenidate.]
[N05AC02, thioridazine, The risk or severity of adverse effects can be increased when Thioridazine is combined with Methylphenidate.]
[N05AF04, thiothixene, The risk or severity of adverse effects can be increased when Thiothixene is combined with Methylphenidate.]
[G04BE06, moxisylyte, The risk or severity of hypertension can be increased when Methylphenidate is combined with Moxisylyte.]
[N05AL03, tiapride, The risk or severity of adverse effects can be increased when Tiapride is combined with Methylphenidate.]
[S01ED01, timolol, Methylphenidate may decrease the antihypertensive activities of Timolol.]
[M02AX02, tolazoline, Methylphenidate may decrease the antihypertensive activities of Tolazoline.]
[M02AA21, tolmetin, The risk or severity of hypertension can be increased when Methylphenidate is combined with Tolmetin.]
[N06AF04, tranylcypromine, Tranylcypromine may increase the hypertensive activities of Methylphenidate.]
[N06AX05, trazodone, The risk or severity of hypertension can be increased when Methylphenidate is combined with Trazodone.]
[C03AA06, trichlormethiazide, Methylphenidate may decrease the antihypertensive activities of Trichlormethiazide.]
[N05AB06, trifluoperazine, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Methylphenidate.]
[N05AD02, trifluperidol, The risk or severity of adverse effects can be increased when Trifluperidol is combined with Methylphenidate.]
[N05AA05, triflupromazine, The risk or severity of adverse effects can be increased when Triflupromazine is combined with Methylphenidate.]
[N04AA01, trihexyphenidyl, The risk or severity of adverse effects can be increased when Methylphenidate is combined with Trihexyphenidyl.]
[R06AD01, trimeprazine, The risk or severity of adverse effects can be increased when Alimemazine is combined with Methylphenidate.]
[N03AC02, trimethadione, The therapeutic efficacy of Trimethadione can be decreased when used in combination with Methylphenidate.]
[C02BA01, trimethaphan, Methylphenidate may decrease the antihypertensive activities of Trimethaphan.]
[N06AA06, trimipramine, The risk or severity of adverse effects can be increased when Methylphenidate is combined with Trimipramine.]
[N06AX24, vilazodone, The risk or severity of hypertension can be increased when Methylphenidate is combined with Vilazodone.]
[C09CA09, azilsartan medoxomil, Methylphenidate may decrease the antihypertensive activities of Azilsartan medoxomil.]
[N03AX21, ezogabine, The therapeutic efficacy of Ezogabine can be decreased when used in combination with Methylphenidate.]
[R03AC18, indacaterol, The risk or severity of hypertension can be increased when Methylphenidate is combined with Indacaterol.]
[C04AX07, vincamine, Methylphenidate may decrease the antihypertensive activities of Vincamine.]
[B01AA03, warfarin, The metabolism of Warfarin can be decreased when combined with Methylphenidate.]
[N01AX15, xenon, Methylphenidate may increase the hypertensive activities of Xenon.]
[C03BA10, xipamide, Methylphenidate may decrease the antihypertensive activities of Xipamide.]
[N05AF05, zuclopenthixol, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Methylphenidate.]
[N03AX14, levetiracetam, The therapeutic efficacy of Levetiracetam can be decreased when used in combination with Methylphenidate.]
[A02BC04, rabeprazole, Rabeprazole can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[N05AE04, ziprasidone, The risk or severity of adverse effects can be increased when Ziprasidone is combined with Methylphenidate.]
[N02BA01, aspirin, The risk or severity of hypertension can be increased when Methylphenidate is combined with Acetylsalicylic acid.]
[C07AB03, atenolol, Methylphenidate may decrease the antihypertensive activities of Atenolol.]
[S01FA01, atropine, The risk or severity of hypertension can be increased when Methylphenidate is combined with Atropine.]
[G04BD12, mirabegron, The risk or severity of hypertension can be increased when Methylphenidate is combined with Mirabegron.]
[A02AA05, magnesium silicate, Magnesium silicate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[C01CA18, octopamine, The risk or severity of hypertension can be increased when Methylphenidate is combined with Octopamine.]
[A02AC02, calcium silicate, Calcium silicate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[N05CA04, barbital, The therapeutic efficacy of Barbital can be decreased when used in combination with Methylphenidate.]
[N04BD02, rasagiline, Rasagiline may increase the hypertensive activities of Methylphenidate.]
[C08CA13, lercanidipine, Methylphenidate may decrease the antihypertensive activities of Lercanidipine.]
[N03AX22, perampanel, The therapeutic efficacy of Perampanel can be decreased when used in combination with Methylphenidate.]
[N02CC03, zolmitriptan, The risk or severity of hypertension can be increased when Zolmitriptan is combined with Methylphenidate.]
[N01AA01, ethyl ether, Methylphenidate may increase the hypertensive activities of Diethyl ether.]
[C03AA01, bendroflumethiazide, Methylphenidate may decrease the antihypertensive activities of Bendroflumethiazide.]
[N02BA10, benorilate, The risk or severity of hypertension can be increased when Methylphenidate is combined with Benorilate.]
[N05AD07, benperidol, The risk or severity of adverse effects can be increased when Benperidol is combined with Methylphenidate.]
[M01AH01, celecoxib, The risk or severity of hypertension can be increased when Methylphenidate is combined with Celecoxib.]
[N02CC02, naratriptan, The risk or severity of hypertension can be increased when Methylphenidate is combined with Naratriptan.]
[N04AC01, benztropine, The risk or severity of adverse effects can be increased when Methylphenidate is combined with Benzatropine.]
[R02AX03, benzydamine, The risk or severity of hypertension can be increased when Methylphenidate is combined with Benzydamine.]
[C08EA02, bepridil, Methylphenidate may decrease the antihypertensive activities of Bepridil.]
[C02KX05, riociguat, Methylphenidate may decrease the antihypertensive activities of Riociguat.]
[C02KX04, macitentan, Methylphenidate may decrease the antihypertensive activities of Macitentan.]
[N06AX26, vortioxetine, The risk or severity of hypertension can be increased when Methylphenidate is combined with Vortioxetine.]
[N03AF04, eslicarbazepine, The therapeutic efficacy of Eslicarbazepine can be decreased when used in combination with Methylphenidate.]
[N03AG04, vigabatrin, The therapeutic efficacy of Vigabatrin can be decreased when used in combination with Methylphenidate.]
[C01CA27, droxidopa, The risk or severity of hypertension can be increased when Methylphenidate is combined with Droxidopa.]
[C07AB04, acebutolol, Methylphenidate may decrease the antihypertensive activities of Acebutolol.]
[S01ED02, betaxolol, Methylphenidate may decrease the antihypertensive activities of Betaxolol.]
[C02CC01, bethanidine, Methylphenidate may decrease the antihypertensive activities of Bethanidine.]
[B01AA07, acenocoumarol, The metabolism of Acenocoumarol can be decreased when combined with Methylphenidate.]
[R03AC19, olodaterol, The risk or severity of hypertension can be increased when Methylphenidate is combined with Olodaterol.]
[N05AA04, acepromazine, The risk or severity of adverse effects can be increased when Acepromazine is combined with Methylphenidate.]
[N04AA02, biperiden, The risk or severity of adverse effects can be increased when Methylphenidate is combined with Biperiden.]
[B01AA01, dicumarol, The metabolism of Dicoumarol can be decreased when combined with Methylphenidate.]
[N06AX11, mirtazapine, The risk or severity of hypertension can be increased when Mirtazapine is combined with Methylphenidate.]
[B01AA11, tioclomarol, The metabolism of Tioclomarol can be decreased when combined with Methylphenidate.]
[N05AX16, brexpiprazole, The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Methylphenidate.]
[G02CX02, flibanserin, The risk or severity of hypertension can be increased when Methylphenidate is combined with Flibanserin.]
[A06AD03, magnesium peroxide, Magnesium peroxide can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[N05AX15, cariprazine, The risk or severity of adverse effects can be increased when Cariprazine is combined with Methylphenidate.]
[M02AA25, aceclofenac, The risk or severity of hypertension can be increased when Methylphenidate is combined with Aceclofenac.]
[M01AB11, acemetacin, The risk or severity of hypertension can be increased when Methylphenidate is combined with Acemetacin.]
[S01EC01, acetazolamide, The therapeutic efficacy of Acetazolamide can be decreased when used in combination with Methylphenidate.]
[N05AB07, acetophenazine, The risk or severity of adverse effects can be increased when Acetophenazine is combined with Methylphenidate.]
[A02BC03, lansoprazole, Lansoprazole can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[B01AC27, selexipag, Methylphenidate may decrease the antihypertensive activities of Selexipag.]
[M01AE16, alminoprofen, The risk or severity of hypertension can be increased when Methylphenidate is combined with Alminoprofen.]
[A02AB06, aloglutamol, Aloglutamol can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[N03AX23, brivaracetam, The therapeutic efficacy of Brivaracetam can be decreased when used in combination with Methylphenidate.]
[N04BC01, bromocriptine, The risk or severity of adverse effects can be increased when Methylphenidate is combined with Bromocriptine.]
[A02AD05, aluminum magnesium silicate, Almasilate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[A02AB03, aluminum phosphate, Aluminium phosphate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[N06AA19, amineptin, The risk or severity of adverse effects can be increased when Methylphenidate is combined with Amineptine.]
[C08CA01, amlodipine, Methylphenidate may decrease the antihypertensive activities of Amlodipine.]
[C07AA19, bupranolol, Methylphenidate may decrease the antihypertensive activities of Bupranolol.]
[N05BE01, buspirone, The risk or severity of hypertension can be increased when Methylphenidate is combined with Buspirone.]
[M02AA03, clofezone, Rabeprazole can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[A07EC04, balsalazide, The risk or severity of hypertension can be increased when Methylphenidate is combined with Balsalazide.]
[R03CC12, bambuterol, The risk or severity of hypertension can be increased when Methylphenidate is combined with Bambuterol.]
[N02BF02, pregabalin, The therapeutic efficacy of Pregabalin can be decreased when used in combination with Methylphenidate.]
[N03AX30, beclamide, The therapeutic efficacy of Beclamide can be decreased when used in combination with Methylphenidate.]
[C09AA07, benazepril, Methylphenidate may decrease the antihypertensive activities of Benazepril.]
[A12AA04, calcium carbonate, Calcium carbonate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[J01XX08, linezolid, Linezolid may increase the hypertensive activities of Methylphenidate.]
[N04BD03, safinamide, Safinamide may increase the hypertensive activities of Methylphenidate.]
[A02BX12, bismuth subnitrate, Bismuth subnitrate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[C07AB07, bisoprolol, Methylphenidate may decrease the antihypertensive activities of Bisoprolol.]
[R03AC17, bitolterol, The risk or severity of hypertension can be increased when Methylphenidate is combined with Bitolterol.]
[N04AA11, bornaprine, The risk or severity of adverse effects can be increased when Methylphenidate is combined with Bornaprine.]
[N05AD06, bromperidol, The risk or severity of adverse effects can be increased when Bromperidol is combined with Methylphenidate.]
[N04BX03, budipine, The risk or severity of adverse effects can be increased when Methylphenidate is combined with Budipine.]
[C04AX20, buflomedil, The risk or severity of hypertension can be increased when Methylphenidate is combined with Buflomedil.]
[M01AB07, bumadizone, The risk or severity of hypertension can be increased when Methylphenidate is combined with Bumadizone.]
[N06AA15, butriptyline, The risk or severity of adverse effects can be increased when Methylphenidate is combined with Butriptyline.]
[C09AA01, captopril, Methylphenidate may decrease the antihypertensive activities of Captopril.]
[N03AF01, carbamazepine, The therapeutic efficacy of Carbamazepine can be decreased when used in combination with Methylphenidate.]
[C07AG02, carvedilol, Methylphenidate may decrease the antihypertensive activities of Carvedilol.]
[N03AX24, cannabidiol, The therapeutic efficacy of Cannabidiol can be decreased when used in combination with Methylphenidate.]
[V03AE10, sodium zirconium cyclosilicate, Sodium zirconium cyclosilicate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[C07AB08, celiprolol, Methylphenidate may decrease the antihypertensive activities of Celiprolol.]
[N03AX17, stiripentol, The therapeutic efficacy of Stiripentol can be decreased when used in combination with Methylphenidate.]
[M01AC05, lornoxicam, The risk or severity of hypertension can be increased when Methylphenidate is combined with Lornoxicam.]
[N07XX05, amifampridine, The risk or severity of seizure can be increased when Methylphenidate is combined with Amifampridine.]
[C09AA08, cilazapril, Methylphenidate may decrease the antihypertensive activities of Cilazapril.]
[A03FA08, cinitapride, The risk or severity of hypertension can be increased when Methylphenidate is combined with Cinitapride.]
[N06AX27, esketamine, The risk or severity of hypertension can be increased when Esketamine is combined with Methylphenidate.]
[L04AA42, siponimod, The risk or severity of hypertension can be increased when Methylphenidate is combined with Siponimod.]
[N06BA14, solriamfetol, The risk or severity of hypertension can be increased when Solriamfetol is combined with Methylphenidate.]
[N06AX29, brexanolone, The therapeutic efficacy of Brexanolone can be decreased when used in combination with Methylphenidate.]
[N05BA09, clobazam, The therapeutic efficacy of Clobazam can be decreased when used in combination with Methylphenidate.]
[C09CA06, candesartan, Methylphenidate may decrease the antihypertensive activities of Candesartan.]
[N05AA06, cyamemazine, The risk or severity of adverse effects can be increased when Cyamemazine is combined with Methylphenidate.]
[C03BX03, cicletanine, Methylphenidate may decrease the antihypertensive activities of Cicletanine.]
[N04CX01, istradefylline, The risk or severity of adverse effects can be increased when Methylphenidate is combined with Istradefylline.]
[C03AA09, cyclothiazide, Methylphenidate may decrease the antihypertensive activities of Cyclothiazide.]
[G04BE04, yohimbine, The risk or severity of hypertension can be increased when Methylphenidate is combined with Yohimbine.]
[N03AX25, cenobamate, The therapeutic efficacy of Cenobamate can be decreased when used in combination with Methylphenidate.]
[N05AD10, lumateperone, The risk or severity of adverse effects can be increased when Lumateperone is combined with Methylphenidate.]
[N02CC07, frovatriptan, The risk or severity of hypertension can be increased when Methylphenidate is combined with Frovatriptan.]
[G04CB02, dutasteride, The risk or severity of hypertension can be increased when Methylphenidate is combined with Dutasteride.]
[N02CC06, eletriptan, The risk or severity of hypertension can be increased when Eletriptan is combined with Methylphenidate.]
[M01AH02, rofecoxib, The risk or severity of hypertension can be increased when Methylphenidate is combined with Rofecoxib.]
[C01BD07, dronedarone, The risk or severity of hypertension can be increased when Methylphenidate is combined with Dronedarone.]
[N03AG02, dipropylacetamide, The therapeutic efficacy of Valpromide can be decreased when used in combination with Methylphenidate.]
[C02AA06, methoserpidine, Methylphenidate may decrease the antihypertensive activities of Methoserpidine.]
[N04BX04, opicapone, The risk or severity of adverse effects can be increased when Methylphenidate is combined with Opicapone.]
[C01CA14, dopexamine, The risk or severity of hypertension can be increased when Methylphenidate is combined with Dopexamine.]
[M01AC04, droxicam, The risk or severity of hypertension can be increased when Methylphenidate is combined with Droxicam.]
[L01EX22, selpercatinib, The risk or severity of hypertension can be increased when Methylphenidate is combined with Selpercatinib.]
[M02AA27, dexketoprofen, The risk or severity of hypertension can be increased when Methylphenidate is combined with Dexketoprofen.]
[N05CM02, chlormethiazole, The therapeutic efficacy of Clomethiazole can be decreased when used in combination with Methylphenidate.]
[C08CA17, levamlodipine, Methylphenidate may decrease the antihypertensive activities of Levamlodipine.]
[C03AA04, chlorothiazide, Methylphenidate may decrease the antihypertensive activities of Chlorothiazide.]
[N05AA01, chlorpromazine, The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Methylphenidate.]
[N05AF03, chlorprothixene, The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Methylphenidate.]
[C03BA04, chlorthalidone, Methylphenidate may decrease the antihypertensive activities of Chlorthalidone.]
[N02BA07, ethenzamide, The risk or severity of hypertension can be increased when Methylphenidate is combined with Ethenzamide.]
[N06BX18, vinpocetine, The therapeutic efficacy of Vinpocetine can be decreased when used in combination with Methylphenidate.]
[M01AB08, etodolac, The risk or severity of hypertension can be increased when Methylphenidate is combined with Etodolac.]
[M02AA06, etofenamate, The risk or severity of hypertension can be increased when Methylphenidate is combined with Etofenamate.]
[L01FX21, naxitamab, The risk or severity of hypertension can be increased when Methylphenidate is combined with Naxitamab.]
[N03AX10, felbamate, The therapeutic efficacy of Felbamate can be decreased when used in combination with Methylphenidate.]
[M01AE05, fenbufen, The risk or severity of hypertension can be increased when Methylphenidate is combined with Fenbufen.]
[C01CA19, fenoldopam, Methylphenidate may decrease the antihypertensive activities of Fenoldopam.]
[N06BA08, fenozolone, The risk or severity of hypertension can be increased when Methylphenidate is combined with Fenozolone.]
[G04CB01, finasteride, The risk or severity of hypertension can be increased when Methylphenidate is combined with Finasteride.]
[R03CC15, formoterol, The risk or severity of hypertension can be increased when Methylphenidate is combined with Formoterol.]
[N01AB05, trichloroethylene, Methylphenidate may increase the hypertensive activities of Trichloroethylene.]
[H04AA02, dasiglucagon, Methylphenidate may decrease the antihypertensive activities of Dasiglucagon.]
[A02BA01, cimetidine, The therapeutic efficacy of Methylphenidate can be decreased when used in combination with Cimetidine.]
[N02BF01, gabapentin, The therapeutic efficacy of Gabapentin can be decreased when used in combination with Methylphenidate.]
[V09AB03, ioflupane I-123, Methylphenidate may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.]
[M01AG01, mefenamic acid, The risk or severity of hypertension can be increased when Methylphenidate is combined with Mefenamic acid.]
[R03CC13, clenbuterol, The risk or severity of hypertension can be increased when Methylphenidate is combined with Clenbuterol.]
[N06AA04, clomipramine, The risk or severity of adverse effects can be increased when Methylphenidate is combined with Clomipramine.]
[N03AE01, clonazepam, The therapeutic efficacy of Clonazepam can be decreased when used in combination with Methylphenidate.]
[S01EA04, clonidine, The risk or severity of adverse effects can be increased when Methylphenidate is combined with Clonidine.]
[A02BC08, vonoprazan, Vonoprazan can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[N05AH06, clothiapine, The risk or severity of adverse effects can be increased when Clothiapine is combined with Methylphenidate.]
[N05AH02, clozapine, The risk or severity of adverse effects can be increased when Clozapine is combined with Methylphenidate.]
[C02KB01, metyrosine, Methylphenidate may decrease the antihypertensive activities of Metyrosine.]
[M01AX13, proquazone, The risk or severity of hypertension can be increased when Methylphenidate is combined with Proquazone.]
[A02AD04, hydrotalcite, Hydrotalcite can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[N01AB07, desflurane, Methylphenidate may increase the hypertensive activities of Desflurane.]
[C04AX28, ifenprodil, The risk or severity of adverse effects can be increased when Methylphenidate is combined with Ifenprodil.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of hypertension can be increased when Methylphenidate is combined with Imidazole salicylate.]
[B01AC10, indobufen, The risk or severity of hypertension can be increased when Methylphenidate is combined with Indobufen.]
[M01AH03, valdecoxib, The risk or severity of hypertension can be increased when Methylphenidate is combined with Valdecoxib.]
[A03AX10, isometheptene, The risk or severity of hypertension can be increased when Methylphenidate is combined with Isometheptene.]
[N02CC05, almotriptan, The risk or severity of hypertension can be increased when Methylphenidate is combined with Almotriptan.]
[M01AH04, parecoxib, The risk or severity of hypertension can be increased when Methylphenidate is combined with Parecoxib.]
[M01AA06, kebuzone, The risk or severity of hypertension can be increased when Methylphenidate is combined with Kebuzone.]
[A02BC05, esomeprazole, Esomeprazole can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[C08CA09, lacidipine, Methylphenidate may decrease the antihypertensive activities of Lacidipine.]
[N03AX09, lamotrigine, The therapeutic efficacy of Lamotrigine can be decreased when used in combination with Methylphenidate.]
[N07BC04, lofexidine, Methylphenidate may decrease the antihypertensive activities of Lofexidine.]
[M01AB09, lonazolac, The risk or severity of hypertension can be increased when Methylphenidate is combined with Lonazolac.]
[M02AA31, loxoprofen, The risk or severity of hypertension can be increased when Methylphenidate is combined with Loxoprofen.]
[C09AA03, lisinopril, Methylphenidate may decrease the antihypertensive activities of Lisinopril.]
[A02AD02, magaldrate, Magaldrate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[A06AD01, magnesium carbonate, Magnesium carbonate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[C08CA11, manidipine, Methylphenidate may decrease the antihypertensive activities of Manidipine.]
[A08AA09, mefenorex, The risk or severity of hypertension can be increased when Methylphenidate is combined with Mefenorex.]
[N04AA03, methixene, The risk or severity of adverse effects can be increased when Methylphenidate is combined with Metixene.]
[R03CB02, methoxyphenamine, The risk or severity of hypertension can be increased when Methylphenidate is combined with Methoxyphenamine.]
[C03DA04, eplerenone, Methylphenidate may decrease the antihypertensive activities of Eplerenone.]
[N05AD03, metylperon, The risk or severity of adverse effects can be increased when Melperone is combined with Methylphenidate.]
[C03AA07, cyclopenthiazide, Methylphenidate may decrease the antihypertensive activities of Cyclopenthiazide.]
[N06AX07, minaprine, Minaprine may increase the hypertensive activities of Methylphenidate.]
[S01XA18, cyclosporine, The risk or severity of hypertension can be increased when Cyclosporine is combined with Methylphenidate.]
[N06AG02, moclobemide, Moclobemide may increase the hypertensive activities of Methylphenidate.]
[C09AA13, moexipril, Methylphenidate may decrease the antihypertensive activities of Moexipril.]
[M02AA02, mofebutazone, The risk or severity of hypertension can be increased when Methylphenidate is combined with Mofebutazone.]
[M01AX22, morniflumate, The risk or severity of hypertension can be increased when Methylphenidate is combined with Morniflumate.]
[C02AC05, moxonidine, Methylphenidate may decrease the antihypertensive activities of Moxonidine.]
[M01AH05, etoricoxib, The risk or severity of hypertension can be increased when Methylphenidate is combined with Etoricoxib.]
[C02CC04, debrisoquin, Methylphenidate may decrease the antihypertensive activities of Debrisoquine.]
[M01AX01, nabumetone, The risk or severity of hypertension can be increased when Methylphenidate is combined with Nabumetone.]
[C07AB12, nebivolol, Methylphenidate may decrease the antihypertensive activities of Nebivolol.]
[N06AX06, nefazodone, The risk or severity of hypertension can be increased when Methylphenidate is combined with Nefazodone.]
[C01DX16, nicorandil, Methylphenidate may decrease the antihypertensive activities of Nicorandil.]
[N03AG06, tiagabine, The therapeutic efficacy of Tiagabine can be decreased when used in combination with Methylphenidate.]
[C01CA23, theodrenaline, The risk or severity of hypertension can be increased when Methylphenidate is combined with Theodrenaline.]
[C01CA05, norfenefrine, The risk or severity of hypertension can be increased when Methylphenidate is combined with Norfenefrine.]
[G04BD08, solifenacin, The risk or severity of hypertension can be increased when Methylphenidate is combined with Solifenacin.]
[A07EC03, olsalazine, The risk or severity of hypertension can be increased when Methylphenidate is combined with Olsalazine.]
[N06AA01, desipramine, The risk or severity of adverse effects can be increased when Methylphenidate is combined with Desipramine.]
[H01BA02, desmopressin, The risk or severity of hypertension can be increased when Desmopressin is combined with Methylphenidate.]
[C09XA02, aliskiren, Methylphenidate may decrease the antihypertensive activities of Aliskiren.]
[M01AE12, oxaprozin, The risk or severity of hypertension can be increased when Methylphenidate is combined with Oxaprozin.]
[N03AF02, oxcarbazepine, The therapeutic efficacy of Oxcarbazepine can be decreased when used in combination with Methylphenidate.]
[N04AA08, dexetimide, The risk or severity of adverse effects can be increased when Methylphenidate is combined with Dexetimide.]
[N06BA02, dextroamphetamine, The risk or severity of hypertension can be increased when Amphetamine is combined with Methylphenidate.]
[N03AC01, paramethadione, The therapeutic efficacy of Paramethadione can be decreased when used in combination with Methylphenidate.]
[N05BA01, diazepam, The therapeutic efficacy of Diazepam can be decreased when used in combination with Methylphenidate.]
[N03AX07, phenacemide, The therapeutic efficacy of Phenacemide can be decreased when used in combination with Methylphenidate.]
[V03AH01, diazoxide, Methylphenidate may decrease the antihypertensive activities of Diazoxide.]
[N03AD02, phensuximide, The therapeutic efficacy of Phensuximide can be decreased when used in combination with Methylphenidate.]
[N06AA08, dibenzepin, The risk or severity of adverse effects can be increased when Methylphenidate is combined with Dibenzepin.]
[S01BC03, diclofenac, The risk or severity of hypertension can be increased when Methylphenidate is combined with Diclofenac.]
[C02DG01, pinacidil, Methylphenidate may decrease the antihypertensive activities of Pinacidil.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Pipamperone is combined with Methylphenidate.]
[R03CC07, pirbuterol, The risk or severity of hypertension can be increased when Methylphenidate is combined with Pirbuterol.]
[A08AA03, diethylpropion, The risk or severity of hypertension can be increased when Methylphenidate is combined with Diethylpropion.]
[C08CA03, isradipine, Methylphenidate may decrease the antihypertensive activities of Isradipine.]
[N02BA11, diflunisal, The risk or severity of hypertension can be increased when Methylphenidate is combined with Diflunisal.]
[C02DB01, dihydralazine, Methylphenidate may decrease the antihypertensive activities of Dihydralazine.]
[C04AE04, dihydroergocristine, The risk or severity of hypertension can be increased when Methylphenidate is combined with Dihydroergocristine.]
[N02CA01, dihydroergotamine, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Methylphenidate.]
[B01AC21, treprostinil, Methylphenidate may decrease the antihypertensive activities of Treprostinil.]
[C08DB01, diltiazem, Methylphenidate may decrease the antihypertensive activities of Diltiazem.]
[R03CC08, procaterol, The risk or severity of hypertension can be increased when Methylphenidate is combined with Procaterol.]
[N03AG05, progabide, The risk or severity of adverse effects can be increased when Methylphenidate is combined with Progabide.]
[N02BB04, propyphenazone, The risk or severity of hypertension can be increased when Methylphenidate is combined with Propyphenazone.]
[M01AB14, proglumetacin, The risk or severity of hypertension can be increased when Methylphenidate is combined with Proglumetacin.]
[C09AA06, quinapril, Methylphenidate may decrease the antihypertensive activities of Quinapril.]
[N06BA11, dexmethylphenidate, The risk or severity of hypertension can be increased when Methylphenidate is combined with Dexmethylphenidate.]
[N06AA23, quinupramine, The risk or severity of adverse effects can be increased when Methylphenidate is combined with Quinupramine.]
[C09AA05, ramipril, Methylphenidate may decrease the antihypertensive activities of Ramipril.]
[N05AL04, remoxipride, The risk or severity of adverse effects can be increased when Remoxipride is combined with Methylphenidate.]
[R03CC14, reproterol, The risk or severity of hypertension can be increased when Methylphenidate is combined with Reproterol.]
[P03AA04, disulfiram, The risk or severity of adverse effects can be increased when Disulfiram is combined with Methylphenidate.]
[N07XX02, riluzole, The therapeutic efficacy of Riluzole can be decreased when used in combination with Methylphenidate.]
[N05AX08, risperidone, The risk or severity of adverse effects can be increased when Risperidone is combined with Methylphenidate.]
[G04BE08, tadalafil, Methylphenidate may decrease the antihypertensive activities of Tadalafil.]
[S01BC05, ketorolac, The risk or severity of hypertension can be increased when Methylphenidate is combined with Ketorolac.]
[C02KX02, ambrisentan, Methylphenidate may decrease the antihypertensive activities of Ambrisentan.]
[N02BA06, salsalate, The risk or severity of hypertension can be increased when Methylphenidate is combined with Salsalate.]
[R03AC12, salmeterol, The risk or severity of hypertension can be increased when Methylphenidate is combined with Salmeterol.]
[C01CA07, dobutamine, The risk or severity of hypertension can be increased when Methylphenidate is combined with Dobutamine.]
[C01CA04, dopamine, The risk or severity of hypertension can be increased when Methylphenidate is combined with Dopamine.]
[N06AA16, dothiepin, The risk or severity of adverse effects can be increased when Methylphenidate is combined with Dosulepin.]
[R07AB01, doxapram, The risk or severity of hypertension can be increased when Methylphenidate is combined with Doxapram.]
[N06AA12, doxepin, The therapeutic efficacy of Methylphenidate can be decreased when used in combination with Doxepin.]
[N01AB08, sevoflurane, Methylphenidate may increase the hypertensive activities of Sevoflurane.]
[N05AD08, droperidol, The risk or severity of adverse effects can be increased when Droperidol is combined with Methylphenidate.]
[B05XA02, sodium bicarbonate, Sodium bicarbonate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[C09AA11, spirapril, Methylphenidate may decrease the antihypertensive activities of Spirapril.]
[N05AL02, sultopride, The risk or severity of adverse effects can be increased when Sultopride is combined with Methylphenidate.]
[N02CC01, sumatriptan, The risk or severity of hypertension can be increased when Methylphenidate is combined with Sumatriptan.]
[C07AB13, talinolol, Methylphenidate may decrease the antihypertensive activities of Talinolol.]
[M01AC02, tenoxicam, The risk or severity of hypertension can be increased when Methylphenidate is combined with Tenoxicam.]
[G04CA03, terazosin, Methylphenidate may decrease the antihypertensive activities of Terazosin.]
[S01GA02, tetrahydrozoline, The risk or severity of hypertension can be increased when Methylphenidate is combined with Tetryzoline.]
[N05AB05, thiopropazate, The risk or severity of adverse effects can be increased when Thiopropazate is combined with Methylphenidate.]
[N06AX14, tianeptine, The risk or severity of adverse effects can be increased when Methylphenidate is combined with Tianeptine.]
[C09AA02, enalapril, Methylphenidate may decrease the antihypertensive activities of Enalapril.]
[M01AG02, tolfenamic acid, The risk or severity of hypertension can be increased when Methylphenidate is combined with Tolfenamic acid.]
[N06AG03, toloxatone, Toloxatone may increase the hypertensive activities of Methylphenidate.]
[N03AX11, topiramate, The therapeutic efficacy of Topiramate can be decreased when used in combination with Methylphenidate.]
[C03CA04, torsemide, Methylphenidate may decrease the antihypertensive activities of Torasemide.]
[R01AA09, tramazoline, The risk or severity of hypertension can be increased when Methylphenidate is combined with Tramazoline.]
[C09AA10, trandolapril, Methylphenidate may decrease the antihypertensive activities of Trandolapril.]
[N04AA12, tropatepine, The risk or severity of adverse effects can be increased when Methylphenidate is combined with Tropatepine.]
[R03CC11, tulobuterol, The risk or severity of hypertension can be increased when Methylphenidate is combined with Tulobuterol.]
[N01AB04, enflurane, Methylphenidate may increase the hypertensive activities of Enflurane.]
[C02CA06, urapidil, Methylphenidate may decrease the antihypertensive activities of Urapidil.]
[N05AL06, veralipride, The risk or severity of adverse effects can be increased when Veralipride is combined with Methylphenidate.]
[S01FB02, ephedrine, The risk or severity of hypertension can be increased when Methylphenidate is combined with Ephedrine.]
[S01GX10, epinastine, The therapeutic efficacy of Methylphenidate can be decreased when used in combination with Epinastine.]
[C01CX07, xamoterol, The risk or severity of hypertension can be increased when Methylphenidate is combined with Xamoterol.]
[S01GA03, xylometazoline, The risk or severity of hypertension can be increased when Methylphenidate is combined with Xylometazoline.]
[S01EA01, epinephrine, The risk or severity of hypertension can be increased when Methylphenidate is combined with Epinephrine.]
[C09AA15, zofenopril, Methylphenidate may decrease the antihypertensive activities of Zofenopril.]
[M01AB04, zomepirac, The risk or severity of hypertension can be increased when Methylphenidate is combined with Zomepirac.]
[N03AX15, zonisamide, The therapeutic efficacy of Zonisamide can be decreased when used in combination with Methylphenidate.]
[N05AX11, zotepine, The risk or severity of adverse effects can be increased when Zotepine is combined with Methylphenidate.]
[C02AC02, guanfacine, Methylphenidate may decrease the antihypertensive activities of Guanfacine.]
[C01BG01, moricizine, The risk or severity of adverse effects can be increased when Moricizine is combined with Methylphenidate.]
[G02AB03, ergonovine, The risk or severity of hypertension can be increased when Methylphenidate is combined with Ergometrine.]
[C04AE01, ergoloid mesylates, USP, The risk or severity of hypertension can be increased when Methylphenidate is combined with Ergoloid mesylate.]
[N02CA02, ergotamine, The risk or severity of hypertension can be increased when Methylphenidate is combined with Ergotamine.]
[N03AG01, valproic acid, The therapeutic efficacy of Valproic acid can be decreased when used in combination with Methylphenidate.]
[N05CD04, estazolam, The therapeutic efficacy of Estazolam can be decreased when used in combination with Methylphenidate.]
[A02BC02, pantoprazole, Pantoprazole can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[C01CA15, gepefrine, The risk or severity of hypertension can be increased when Methylphenidate is combined with Gepefrine.]
[N04AA05, profenamine, The risk or severity of adverse effects can be increased when Methylphenidate is combined with Profenamine.]
[N03AD01, ethosuximide, The therapeutic efficacy of Ethosuximide can be decreased when used in combination with Methylphenidate.]
[N03AB01, ethotoin, The therapeutic efficacy of Ethotoin can be decreased when used in combination with Methylphenidate.]
[M01AC06, meloxicam, The risk or severity of hypertension can be increased when Methylphenidate is combined with Meloxicam.]
[C01CA01, etilefrine, The risk or severity of hypertension can be increased when Methylphenidate is combined with Etilefrine.]
[N01AX07, etomidate, The risk or severity of hypertension can be increased when Etomidate is combined with Methylphenidate.]
[N05AE03, sertindole, The risk or severity of adverse effects can be increased when Sertindole is combined with Methylphenidate.]
[A02BA04, nizatidine, The therapeutic efficacy of Methylphenidate can be decreased when used in combination with Nizatidine.]
[N06AX12, bupropion, The risk or severity of seizure can be increased when Bupropion is combined with Methylphenidate.]
[A02BA03, famotidine, The therapeutic efficacy of Methylphenidate can be decreased when used in combination with Famotidine.]
[C08CA02, felodipine, Methylphenidate may decrease the antihypertensive activities of Felodipine.]
[N03AX26, fenfluramine, The therapeutic efficacy of Fenfluramine can be decreased when used in combination with Methylphenidate.]
[M01AE04, fenoprofen, The risk or severity of hypertension can be increased when Methylphenidate is combined with Fenoprofen.]
[R03CC04, fenoterol, The risk or severity of hypertension can be increased when Methylphenidate is combined with Fenoterol.]
[N02AB03, fentanyl, The risk or severity of hypertension can be increased when Methylphenidate is combined with Fentanyl.]
[R03CC02, albuterol, The risk or severity of hypertension can be increased when Methylphenidate is combined with Salbutamol.]
[N02BG04, floctafenine, The risk or severity of hypertension can be increased when Methylphenidate is combined with Floctafenine.]
[N07CA03, flunarizine, The therapeutic efficacy of Flunarizine can be decreased when used in combination with Methylphenidate.]
[N06AA14, melitracen, The risk or severity of adverse effects can be increased when Methylphenidate is combined with Melitracen.]
[V03AZ01, ethanol, The risk or severity of adverse effects can be increased when Ethanol is combined with Methylphenidate.]
[N05AF01, flupenthixol, The risk or severity of adverse effects can be increased when Flupentixol is combined with Methylphenidate.]
[N05AB02, fluphenazine, The risk or severity of adverse effects can be increased when Fluphenazine is combined with Methylphenidate.]
[S01BC04, flurbiprofen, The risk or severity of hypertension can be increased when Methylphenidate is combined with Flurbiprofen.]
[N05AG01, fluspirilene, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Methylphenidate.]
[N06BX17, adrafinil, The risk or severity of hypertension can be increased when Methylphenidate is combined with Adrafinil.]
[G01AX06, furazolidone, Furazolidone may increase the hypertensive activities of Methylphenidate.]
[C03CA01, furosemide, Methylphenidate may decrease the antihypertensive activities of Furosemide.]
[N05AL05, amisulpride, The risk or severity of adverse effects can be increased when Amisulpride is combined with Methylphenidate.]
[N03AA04, barbexaclone, The therapeutic efficacy of Barbexaclone can be decreased when used in combination with Methylphenidate.]
[N04BC06, cabergoline, The risk or severity of adverse effects can be increased when Methylphenidate is combined with Cabergoline.]
[N03AD03, methsuximide, The therapeutic efficacy of Methsuximide can be decreased when used in combination with Methylphenidate.]
[N01AH02, alfentanil, The risk or severity of hypertension can be increased when Methylphenidate is combined with Alfentanil.]
[N05CM18, dexmedetomidine, The risk or severity of hypertension can be increased when Methylphenidate is combined with Dexmedetomidine.]
[C05AE01, nitroglycerin, Methylphenidate may decrease the antihypertensive activities of Nitroglycerin.]
[C02CA04, doxazosin, Methylphenidate may decrease the antihypertensive activities of Doxazosin.]
[C07AB09, esmolol, Methylphenidate may decrease the antihypertensive activities of Esmolol.]
[B01AA12, fluindione, The metabolism of Fluindione can be decreased when combined with Methylphenidate.]
[C09AA09, fosinopril, Methylphenidate may decrease the antihypertensive activities of Fosinopril.]
[S01EX01, guanethidine, Methylphenidate may decrease the antihypertensive activities of Guanethidine.]
[N05AD01, haloperidol, The risk or severity of adverse effects can be increased when Haloperidol is combined with Methylphenidate.]
[N01AB01, halothane, Methylphenidate may increase the hypertensive activities of Halothane.]
[N05AH04, quetiapine, The risk or severity of adverse effects can be increased when Quetiapine is combined with Methylphenidate.]
[C09CA01, losartan, Methylphenidate may decrease the antihypertensive activities of Losartan.]
[A07EC02, mesalamine, The risk or severity of hypertension can be increased when Mesalazine is combined with Methylphenidate.]
[N05CA16, hexobarbital, The therapeutic efficacy of Hexobarbital can be decreased when used in combination with Methylphenidate.]
[R03CC05, hexoprenaline, The risk or severity of hypertension can be increased when Methylphenidate is combined with Hexoprenaline.]
[C08CA10, nilvadipine, Methylphenidate may decrease the antihypertensive activities of Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of hypertension can be increased when Methylphenidate is combined with Nimesulide.]
[C09AA04, perindopril, Methylphenidate may decrease the antihypertensive activities of Perindopril.]
[C02DB02, hydralazine, Methylphenidate may decrease the antihypertensive activities of Hydralazine.]
[C03AA03, hydrochlorothiazide, Methylphenidate may decrease the antihypertensive activities of Hydrochlorothiazide.]
[C03AA02, hydroflumethiazide, Methylphenidate may decrease the antihypertensive activities of Hydroflumethiazide.]
[G04BD06, propiverine, The risk or severity of hypertension can be increased when Methylphenidate is combined with Propiverine.]
[N05AX07, prothipendyl, The risk or severity of adverse effects can be increased when Prothipendyl is combined with Methylphenidate.]
[C02AC06, rilmenidine, Methylphenidate may decrease the antihypertensive activities of Rilmenidine.]
[R02AX02, ibuprofen, The risk or severity of hypertension can be increased when Methylphenidate is combined with Ibuprofen.]
[N01AH03, sufentanil, The risk or severity of hypertension can be increased when Methylphenidate is combined with Sufentanil.]
[N06AA02, imipramine, The risk or severity of adverse effects can be increased when Methylphenidate is combined with Imipramine.]
[M03BX02, tizanidine, The therapeutic efficacy of Tizanidine can be decreased when used in combination with Methylphenidate.]
[C03BA11, indapamide, Methylphenidate may decrease the antihypertensive activities of Indapamide.]
[S01BC01, indomethacin, The risk or severity of hypertension can be increased when Indomethacin is combined with Methylphenidate.]
[C02CA02, indoramin, Methylphenidate may decrease the antihypertensive activities of Indoramin.]
[C07AA01, alprenolol, Methylphenidate may decrease the antihypertensive activities of Alprenolol.]
[N06AA13, iprindole, The risk or severity of adverse effects can be increased when Methylphenidate is combined with Iprindole.]
[N06AF05, iproniazid, Iproniazid may increase the hypertensive activities of Methylphenidate.]
[N05AA07, chlorproethazine, The risk or severity of adverse effects can be increased when Chlorproethazine is combined with Methylphenidate.]
[N06AF01, isocarboxazid, Isocarboxazid may increase the hypertensive activities of Methylphenidate.]
[R03CC06, isoetharine, The risk or severity of hypertension can be increased when Isoetharine is combined with Methylphenidate.]
[C09AA16, imidapril, Methylphenidate may decrease the antihypertensive activities of Imidapril.]
[N01AB06, isoflurane, Methylphenidate may increase the hypertensive activities of Isoflurane.]
[N04BX02, entacapone, The risk or severity of adverse effects can be increased when Methylphenidate is combined with Entacapone.]
[R03CB01, isoproterenol, The risk or severity of hypertension can be increased when Methylphenidate is combined with Isoprenaline.]
[C04AA01, isoxsuprine, The risk or severity of hypertension can be increased when Methylphenidate is combined with Isoxsuprine.]
[A02AB01, aluminum hydroxide, Aluminum hydroxide can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[C02KD01, ketanserin, Methylphenidate may decrease the antihypertensive activities of Ketanserin.]
[N05AH03, olanzapine, The therapeutic efficacy of Methylphenidate can be decreased when used in combination with Olanzapine.]
[M02AA10, ketoprofen, The risk or severity of hypertension can be increased when Methylphenidate is combined with Ketoprofen.]
[C01CA22, arbutamine, The risk or severity of hypertension can be increased when Methylphenidate is combined with Arbutamine.]
[N04BC09, rotigotine, The risk or severity of adverse effects can be increased when Methylphenidate is combined with Rotigotine.]
[M01AE11, tiaprofenic acid, The risk or severity of hypertension can be increased when Methylphenidate is combined with Tiaprofenic acid.]
[C07AG01, labetalol, Methylphenidate may decrease the antihypertensive activities of Labetalol.]
[N04BB01, amantadine, The risk or severity of adverse effects can be increased when Methylphenidate is combined with Amantadine.]
[C02AA05, deserpidine, Methylphenidate may decrease the antihypertensive activities of Deserpidine.]
[N03AX18, lacosamide, The therapeutic efficacy of Lacosamide can be decreased when used in combination with Methylphenidate.]
[N04BA01, levodopa, The risk or severity of adverse effects can be increased when Methylphenidate is combined with Levodopa.]
[N02CA07, lisuride, The risk or severity of adverse effects can be increased when Methylphenidate is combined with Lisuride.]
[N06AA07, lofepramine, The risk or severity of adverse effects can be increased when Methylphenidate is combined with Lofepramine.]
[N05BA06, lorazepam, The therapeutic efficacy of Lorazepam can be decreased when used in combination with Methylphenidate.]
[N05AH01, loxapine, The risk or severity of adverse effects can be increased when Loxapine is combined with Methylphenidate.]
[G04BX01, magnesium hydroxide, Magnesium hydroxide can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[A12CC10, magnesium oxide, Magnesium oxide can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Magnesium sulfate can be decreased when used in combination with Methylphenidate.]
[C02BB01, mecamylamine, Methylphenidate may decrease the antihypertensive activities of Mecamylamine.]
[M02AA18, meclofenamic acid, The risk or severity of hypertension can be increased when Methylphenidate is combined with Meclofenamic acid.]
[N05BA03, medazepam, The therapeutic efficacy of Medazepam can be decreased when used in combination with Methylphenidate.]
[N06DX01, memantine, The risk or severity of adverse effects can be increased when Methylphenidate is combined with Memantine.]
[C01CA11, mephentermine, The risk or severity of hypertension can be increased when Methylphenidate is combined with Mephentermine.]
[N03AB04, mephenytoin, The therapeutic efficacy of Mephenytoin can be decreased when used in combination with Methylphenidate.]
[N03AA01, mephobarbital, The serum concentration of Methylphenobarbital can be increased when it is combined with Methylphenidate.]
[N05AC03, mesoridazine, The risk or severity of adverse effects can be increased when Mesoridazine is combined with Methylphenidate.]
[N05AX13, paliperidone, The risk or severity of adverse effects can be increased when Paliperidone is combined with Methylphenidate.]
[C01CA09, metaraminol, The risk or severity of hypertension can be increased when Methylphenidate is combined with Metaraminol.]
[N06BA03, methamphetamine, The risk or severity of hypertension can be increased when Methylphenidate is combined with Metamfetamine.]
[A03AB07, methantheline, The therapeutic efficacy of Methylphenidate can be decreased when used in combination with Methantheline.]
[N03AA30, metharbital, The therapeutic efficacy of Metharbital can be decreased when used in combination with Methylphenidate.]
[G02CB05, metergoline, The risk or severity of hypertension can be increased when Methylphenidate is combined with Metergoline.]
[N05CA15, methohexital, The therapeutic efficacy of Methohexital can be decreased when used in combination with Methylphenidate.]
[N05AA02, methotrimeprazine, The risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Methylphenidate.]
[C01CA10, methoxamine, The risk or severity of hypertension can be increased when Methylphenidate is combined with Methoxamine.]
[N02BG09, methoxyflurane, Methylphenidate may increase the hypertensive activities of Methoxyflurane.]
[C02AB01, methyldopa, Methylphenidate may decrease the antihypertensive activities of Methyldopa.]
[V04CG05, methylene blue, Methylene blue may increase the hypertensive activities of Methylphenidate.]
[G02AB01, methylergonovine, The risk or severity of hypertension can be increased when Methylergometrine is combined with Methylphenidate.]
[N03AF03, rufinamide, The therapeutic efficacy of Rufinamide can be decreased when used in combination with Methylphenidate.]
[N02CA04, methysergide, The risk or severity of hypertension can be increased when Methysergide is combined with Methylphenidate.]
[C03BA08, metolazone, Methylphenidate may decrease the antihypertensive activities of Metolazone.]
[C07AB02, metoprolol, Methylphenidate may decrease the antihypertensive activities of Metoprolol.]
[N06AX03, mianserin, The risk or severity of hypertension can be increased when Methylphenidate is combined with Mianserin.]
[N02BB03, aminopyrine, The risk or severity of hypertension can be increased when Methylphenidate is combined with Aminophenazone.]
[C01CA17, midodrine, The risk or severity of hypertension can be increased when Midodrine is combined with Methylphenidate.]
[C09CA03, valsartan, Methylphenidate may decrease the antihypertensive activities of Valsartan.]
[D11AX01, minoxidil, Methylphenidate may decrease the antihypertensive activities of Minoxidil.]
[N06BA12, lisdexamfetamine, The risk or severity of hypertension can be increased when Methylphenidate is combined with Lisdexamfetamine.]
[N05AE02, molindone, The risk or severity of adverse effects can be increased when Molindone is combined with Methylphenidate.]
[N06AA09, amitriptyline, The risk or severity of adverse effects can be increased when Methylphenidate is combined with Amitriptyline.]
[N05CA02, amobarbital, The therapeutic efficacy of Amobarbital can be decreased when used in combination with Methylphenidate.]
[N06AA17, amoxapine, The risk or severity of adverse effects can be increased when Amoxapine is combined with Methylphenidate.]
[N03AB05, fosphenytoin, The serum concentration of Fosphenytoin can be increased when it is combined with Methylphenidate.]
[C07AA12, nadolol, Methylphenidate may decrease the antihypertensive activities of Nadolol.]
[N04BC04, ropinirole, The risk or severity of adverse effects can be increased when Methylphenidate is combined with Ropinirole.]
[S01GA01, naphazoline, The risk or severity of hypertension can be increased when Methylphenidate is combined with Naphazoline.]
[N06BA01, amphetamine, The risk or severity of hypertension can be increased when Amphetamine is combined with Methylphenidate.]
[M02AA12, naproxen, The risk or severity of hypertension can be increased when Methylphenidate is combined with Naproxen.]
[N04BX01, tolcapone, The risk or severity of adverse effects can be increased when Methylphenidate is combined with Tolcapone.]
[N01AH06, remifentanil, The risk or severity of hypertension can be increased when Methylphenidate is combined with Remifentanil.]
[N05AX14, iloperidone, The risk or severity of adverse effects can be increased when Iloperidone is combined with Methylphenidate.]
[C09CA07, telmisartan, Methylphenidate may decrease the antihypertensive activities of Telmisartan.]
[N06AF02, nialamide, Nialamide may increase the hypertensive activities of Methylphenidate.]
[C08CA04, nicardipine, Methylphenidate may decrease the antihypertensive activities of Nicardipine.]
[C04AE02, nicergoline, The risk or severity of hypertension can be increased when Methylphenidate is combined with Nicergoline.]
[M02AA17, niflumic acid, The risk or severity of hypertension can be increased when Methylphenidate is combined with Niflumic acid.]
[C08CA06, nimodipine, Methylphenidate may decrease the antihypertensive activities of Nimodipine.]
[C08CA07, nisoldipine, Methylphenidate may decrease the antihypertensive activities of Nisoldipine.]
[N05CD02, nitrazepam, The therapeutic efficacy of Nitrazepam can be decreased when used in combination with Methylphenidate.]
[C08CA08, nitrendipine, Methylphenidate may decrease the antihypertensive activities of Nitrendipine.]
[N05CF03, zaleplon, The therapeutic efficacy of Zaleplon can be decreased when used in combination with Methylphenidate.]
[N04BC05, pramipexole, The risk or severity of adverse effects can be increased when Methylphenidate is combined with Pramipexole.]
[C02DD01, nitroprusside, Methylphenidate may decrease the antihypertensive activities of Nitroprusside.]
[N01AX13, nitrous oxide, Methylphenidate may increase the hypertensive activities of Nitrous oxide.]
[C01CA03, norepinephrine, The risk or severity of hypertension can be increased when Norepinephrine is combined with Methylphenidate.]
[C02KX01, bosentan, Methylphenidate may decrease the antihypertensive activities of Bosentan.]
[N06AA10, nortriptyline, The risk or severity of adverse effects can be increased when Methylphenidate is combined with Nortriptyline.]
[G02CA02, nylidrin, The risk or severity of hypertension can be increased when Methylphenidate is combined with Nylidrin.]
[A02BC01, omeprazole, Omeprazole can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[N06AA05, opipramol, The risk or severity of adverse effects can be increased when Methylphenidate is combined with Opipramol.]
[R03CB03, metaproterenol, The risk or severity of hypertension can be increased when Methylphenidate is combined with Orciprenaline.]
[C07AA02, oxprenolol, Methylphenidate may decrease the antihypertensive activities of Oxprenolol.]
[C01DX03, oxyfedrine, The risk or severity of hypertension can be increased when Methylphenidate is combined with Oxyfedrine.]
[S01GA04, oxymetazoline, The risk or severity of hypertension can be increased when Methylphenidate is combined with Oxymetazoline.]
[N05AE01, oxypertine, The risk or severity of adverse effects can be increased when Oxypertine is combined with Methylphenidate.]
[S01BC02, oxyphenbutazone, The risk or severity of hypertension can be increased when Methylphenidate is combined with Oxyphenbutazone.]
[N05AH05, asenapine, The therapeutic efficacy of Methylphenidate can be decreased when used in combination with Asenapine.]
[N05CC05, paraldehyde, The therapeutic efficacy of Paraldehyde can be decreased when used in combination with Methylphenidate.]
[C02KC01, pargyline, Pargyline may increase the hypertensive activities of Methylphenidate.]
[C07AA23, penbutolol, Methylphenidate may decrease the antihypertensive activities of Penbutolol.]
[N05AG03, penfluridol, The risk or severity of adverse effects can be increased when Penfluridol is combined with Methylphenidate.]
[N05CA01, pentobarbital, The therapeutic efficacy of Pentobarbital can be decreased when used in combination with Methylphenidate.]
[N05AB10, perazine, The risk or severity of adverse effects can be increased when Perazine is combined with Methylphenidate.]
[N04BC02, pergolide, The risk or severity of adverse effects can be increased when Methylphenidate is combined with Pergolide.]
[N05AB03, perphenazine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Methylphenidate.]
[N06AF03, phenelzine, Phenelzine may increase the hypertensive activities of Methylphenidate.]
[B01AA02, phenindione, The metabolism of Phenindione can be decreased when combined with Methylphenidate.]
[N03AA02, phenobarbital, The serum concentration of Phenobarbital can be increased when it is combined with Methylphenidate.]
[C04AX02, phenoxybenzamine, Methylphenidate may decrease the antihypertensive activities of Phenoxybenzamine.]
[B01AA04, phenprocoumon, The metabolism of Phenprocoumon can be decreased when combined with Methylphenidate.]
[A08AA01, phentermine, The risk or severity of hypertension can be increased when Phentermine is combined with Methylphenidate.]
[V03AB36, phentolamine, Methylphenidate may decrease the antihypertensive activities of Phentolamine.]
[M02AA01, phenylbutazone, The risk or severity of hypertension can be increased when Methylphenidate is combined with Phenylbutazone.]
[S01GA05, phenylephrine, The risk or severity of hypertension can be increased when Phenylephrine is combined with Methylphenidate.]
[A02BC06, dexlansoprazole, Dexlansoprazole can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[R01BA01, phenylpropanolamine, The risk or severity of hypertension can be increased when Phenylpropanolamine is combined with Methylphenidate.]
[N03AB02, phenytoin, The serum concentration of Phenytoin can be increased when it is combined with Methylphenidate.]
[C08CX01, mibefradil, Methylphenidate may decrease the antihypertensive activities of Mibefradil.]
[N05AG02, pimozide, The risk or severity of adverse effects can be increased when Pimozide is combined with Methylphenidate.]
[C07AA03, pindolol, Methylphenidate may decrease the antihypertensive activities of Pindolol.]
[N05AC04, pipothiazine, The risk or severity of adverse effects can be increased when Pipotiazine is combined with Methylphenidate.]
[C09CA02, eprosartan, Methylphenidate may decrease the antihypertensive activities of Eprosartan.]
[N04BC08, piribedil, The risk or severity of adverse effects can be increased when Methylphenidate is combined with Piribedil.]
[S01BC06, piroxicam, The risk or severity of hypertension can be increased when Methylphenidate is combined with Piroxicam.]
[N02CX01, pizotyline, The risk or severity of hypertension can be increased when Methylphenidate is combined with Pizotifen.]
[C09CA04, irbesartan, Methylphenidate may decrease the antihypertensive activities of Irbesartan.]
[C03AA05, polythiazide, Methylphenidate may decrease the antihypertensive activities of Polythiazide.]
[C07AB01, practolol, Methylphenidate may decrease the antihypertensive activities of Practolol.]
[C02CA01, prazosin, Methylphenidate may decrease the antihypertensive activities of Prazosin.]
[N03AA03, primidone, The serum concentration of Primidone can be increased when it is combined with Methylphenidate.]
[S01HA05, procaine, Procaine may increase the hypertensive activities of Methylphenidate.]
[L01XB01, procarbazine, Procarbazine may increase the hypertensive activities of Methylphenidate.]
[N05AB04, prochlorperazine, The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methylphenidate.]
[N04AA04, procyclidine, The risk or severity of adverse effects can be increased when Methylphenidate is combined with Procyclidine.]
[N05AA03, promazine, The risk or severity of adverse effects can be increased when Promazine is combined with Methylphenidate.]
[R06AD02, promethazine, The therapeutic efficacy of Methylphenidate can be decreased when used in combination with Promethazine.]
[C01BC03, propafenone, The risk or severity of hypertension can be increased when Methylphenidate is combined with Propafenone.]
[N05AC01, periciazine, The risk or severity of adverse effects can be increased when Periciazine is combined with Methylphenidate.]
[N05CM06, propiomazine, The risk or severity of hypertension can be increased when Methylphenidate is combined with Propiomazine.]
[N01AX10, propofol, The risk or severity of hypertension can be increased when Methylphenidate is combined with Propofol.]
[C07AA05, propranolol, Methylphenidate may decrease the antihypertensive activities of Propranolol.]
[N02CC04, rizatriptan, The risk or severity of hypertension can be increased when Methylphenidate is combined with Rizatriptan.]
[B01AC09, epoprostenol, Methylphenidate may decrease the antihypertensive activities of Epoprostenol.]
[N06AA11, protriptyline, The risk or severity of adverse effects can be increased when Methylphenidate is combined with Protriptyline.]
[R01BA02, pseudoephedrine, The risk or severity of hypertension can be increased when Methylphenidate is combined with Pseudoephedrine.]
[N05AX12, aripiprazole, The risk or severity of adverse effects can be increased when Aripiprazole is combined with Methylphenidate.]
[N07XX07, dalfampridine, The risk or severity of seizure can be increased when Methylphenidate is combined with Dalfampridine.]
[C01BA01, quinidine, The risk or severity of hypertension can be increased when Methylphenidate is combined with Quinidine.]
[A02BA02, ranitidine, The therapeutic efficacy of Methylphenidate can be decreased when used in combination with Ranitidine.]
[C02AA01, rescinnamine, Methylphenidate may decrease the antihypertensive activities of Rescinnamine.]
[C02AA02, reserpine, Methylphenidate may decrease the antihypertensive activities of Reserpine.]
[R03AC05, rimiterol, The risk or severity of hypertension can be increased when Methylphenidate is combined with Rimiterol.]
[G02CA01, ritodrine, The risk or severity of hypertension can be increased when Methylphenidate is combined with Ritodrine.]
[N02BA05, salicylamide, The risk or severity of hypertension can be increased when Methylphenidate is combined with Salicylamide.]
[A07EC01, sulfasalazine, The risk or severity of hypertension can be increased when Methylphenidate is combined with Sulfasalazine.]
[S01BC08, salicylic acid, The risk or severity of hypertension can be increased when Methylphenidate is combined with Salicylic acid.]
[N05CA06, secobarbital, The therapeutic efficacy of Secobarbital can be decreased when used in combination with Methylphenidate.]
[N04BD01, selegiline, Selegiline may increase the hypertensive activities of Methylphenidate.]
[N06AF04, tranylcypromine, Amphetamine and derivatives - monoamine oxidase (MAO) inhibitors]
[N06AF01, isocarboxazid, Amphetamine and derivatives - monoamine oxidase (MAO) inhibitors]
[N06AF03, phenelzine, Amphetamine and derivatives - monoamine oxidase (MAO) inhibitors]
[L01XB01, procarbazine, Amphetamine and derivatives - monoamine oxidase (MAO) inhibitors]
[N04BD01, selegiline, Amphetamine and derivatives - monoamine oxidase (MAO) inhibitors]
